statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immuneering price target lowered by $12 at Mizuho, here's why

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Immuneering (IMRX Research Report) on March 27 and set a price target of...

Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1...

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Co. (NASDAQ:IMRX  Get Free Report) has been given a consensus rating of Moderate Buy by the eight brokerages that are currently covering the stock, Marketbeat...

Brokerages Set Immuneering Co. (NASDAQ:IMRX) Target Price at $16.50

Immuneering Corp (IMRX) Director Ann Berman Acquires 57,965 Shares

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone...

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering (NASDAQ:IMRX  Free Report) had its price target reduced by Needham  Company LLC from $20.00 to $15.00 in a research report report published on Friday, MarketBeat reports. They...

Immuneering (NASDAQ:IMRX) PT Lowered to $15.00 at Needham & Company LLC

Immuneering (NASDAQ:IMRX  Get Free Report) was downgraded by research analysts at Jefferies Financial Group from a buy rating to a hold rating in a research note...

Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Jefferies Financial Group

Immuneering price target lowered by $5 at Chardan, here's why

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Volume	44.00
52-Wk High	$11.92
52-Wk Low	$1.47

IMRX Immuneering Corp - Ordinary Shares Class A

About

Feed

News

Earnings

Fundamentals